![Oliver Buck](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oliver Buck
Fondatore presso ITM Isotopen Technologien München AG
Profilo
Oliver Buck is the founder of ITM Isotopen Technologien München AG, where he holds the title of Member-Supervisory Board starting in 2005.
Mr. Buck is also the founder of OncoBeta GmbH.
Currently, Mr. Buck is a Trustee at the International Centers for Precision Oncology Foundation and a Member-Supervisory Board at ITM Isotope Technologies Munich SE.
Previously, Mr. Buck held the position of Non-Independent Non-Executive Director at Telix Pharmaceuticals Ltd.
from 2017 to 2022.
Mr. Buck graduated from Technische Universität München.
Posizioni attive di Oliver Buck
Società | Posizione | Inizio |
---|---|---|
ITM Isotopen Technologien München AG
![]() ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany. | Fondatore | 01/01/2005 |
ITM Isotope Technologies Munich SE
![]() ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011. | Direttore/Membro del Consiglio | 01/01/2012 |
International Centers for Precision Oncology Foundation | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Oliver Buck
Società | Posizione | Fine |
---|---|---|
TELIX PHARMACEUTICALS LIMITED | Direttore/Membro del Consiglio | 18/05/2022 |
OncoBeta GmbH
![]() OncoBeta GmbH Medical SpecialtiesHealth Technology OncoBeta GmbH is a privately held medical device company based in Garching near Munich, Germany. The German company specializes in the development and commercialization of innovative therapies, particularly the epidermal radioisotope therapy Rhenium-SCT® for non-melanoma skin cancers and keloid scars. OncoBeta was founded in 2010 by Oliver Buck and Doris Zur Muehlen, and the CEO is Shannon D. Brown. | Fondatore | - |
Formazione di Oliver Buck
Technische Universität München | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
TELIX PHARMACEUTICALS LIMITED | Health Technology |
Aziende private | 4 |
---|---|
ITM Isotopen Technologien München AG
![]() ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany. | Commercial Services |
OncoBeta GmbH
![]() OncoBeta GmbH Medical SpecialtiesHealth Technology OncoBeta GmbH is a privately held medical device company based in Garching near Munich, Germany. The German company specializes in the development and commercialization of innovative therapies, particularly the epidermal radioisotope therapy Rhenium-SCT® for non-melanoma skin cancers and keloid scars. OncoBeta was founded in 2010 by Oliver Buck and Doris Zur Muehlen, and the CEO is Shannon D. Brown. | Health Technology |
International Centers for Precision Oncology Foundation | |
ITM Isotope Technologies Munich SE
![]() ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011. | Health Technology |
- Borsa valori
- Insiders
- Oliver Buck